Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Expects Increasing Flow Of Adverse Event Reports

Executive Summary

FDA expects the Center for Drug Evaluation & Research to receive 17% more adverse reaction reports in fiscal year 2006 than it received in FY 2004

You may also be interested in...



Serious Adverse Event Periodic Reporting Increased 20% In 2004, FDAer Says

Serious adverse event periodic reports received by the Center for Drug Evaluation & Research increased 20% in 2004, FDA Investigator Thomas Berry said

Serious Adverse Event Periodic Reporting Increased 20% In 2004, FDAer Says

Serious adverse event periodic reports received by the Center for Drug Evaluation & Research increased 20% in 2004, FDA Investigator Thomas Berry said

FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next

HHS is planning a major overhaul of FDA's postmarketing surveillance system as the centerpiece of its next announcement about upgrades to the drug safety regulatory system

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel